Adverum Biotechnologies Management

Management criteria checks 3/4

Adverum Biotechnologies' CEO is Laurent Fischer, appointed in Jun 2020, has a tenure of 4.42 years. total yearly compensation is $1.55M, comprised of 43.4% salary and 56.6% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $532.33K. The average tenure of the management team and the board of directors is 2.8 years and 4.5 years respectively.

Key information

Laurent Fischer

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage	43.4%
CEO tenure	4.4yrs
CEO ownership	0.3%
Management average tenure	2.8yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Laurent Fischer's remuneration changed compared to Adverum Biotechnologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$94m
Jun 30 2024	n/a	n/a	-US$100m
Mar 31 2024	n/a	n/a	-US$113m
Dec 31 2023	US$2m	US$672k	-US$117m
Sep 30 2023	n/a	n/a	-US$126m
Jun 30 2023	n/a	n/a	-US$133m
Mar 31 2023	n/a	n/a	-US$146m
Dec 31 2022	US$3m	US$646k	-US$155m
Sep 30 2022	n/a	n/a	-US$156m
Jun 30 2022	n/a	n/a	-US$154m
Mar 31 2022	n/a	n/a	-US$155m
Dec 31 2021	US$9m	US$621k	-US$146m
Sep 30 2021	n/a	n/a	-US$149m
Jun 30 2021	n/a	n/a	-US$138m
Mar 31 2021	n/a	n/a	-US$123m
Dec 31 2020	US$22m	US$327k	-US$118m

Compensation vs Market: Laurent's total compensation ($USD1.55M) is above average for companies of similar size in the UK market ($USD734.31K).

Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.

CEO

Laurent Fischer (60 yo)

4.4yrs

Tenure

US$1,546,477

Compensation

Dr. Laurent Fischer, M.D., serves as Chair of the Board of Teal Omics Inc. He has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He is Advisor of FORM Life Ventures. He...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Laurent Fischer	President	4.4yrs	US$1.55m	0.34% $ 532.3k
Linda Rubinstein	CFO, Principal Financial Officer & Principal Accounting Officer	1.9yrs	US$2.30m	0.048% $ 75.6k
Kishor Soparkar	Chief Operating Officer	3.4yrs	US$903.02k	0.13% $ 210.1k
Setareh Seyedkazemi	Chief Development Officer	2.8yrs	US$799.36k	0.026% $ 40.6k
Rabia Ozden	Chief Medical Officer	less than a year	US$94.20k	0% $ 0
R. Ramelmeier	Chief Technology Officer	1.3yrs	no data	no data
Romuald Corbau	Chief Scientific Officer	less than a year	no data	no data
John Rakow	Senior VP & General Counsel	3.3yrs	US$1.33m	0.031% $ 49.0k
Dena House	Chief People Officer	5.3yrs	no data	no data
Carla Fiankan	Senior Vice President of Regulatory Affairs	2.8yrs	no data	no data
Michael Steel	Senior Vice President of Quality	3.1yrs	no data	no data
Heikki Jouttijarvi	Senior VP of Manufacturing & Supply Chain Management and Head of Technical Operations	no data	no data	no data

2.8yrs

Average Tenure

56.5yo

Average Age

Experienced Management: 0HA3's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Laurent Fischer	President	4.4yrs	US$1.55m	0.34% $ 532.3k
James Scopa	Independent Director	5.5yrs	US$111.70k	0.050% $ 78.1k
Scott Whitcup	Independent Director	4.6yrs	US$106.70k	0% $ 0
David Boyer	Scientific Advisory Board Member	no data	no data	no data
C. Machado	Independent Chairman	7.7yrs	US$163.80k	0.042% $ 66.7k
Jeffrey Heier	Scientific Advisory Board Member	no data	no data	no data
Reed Tuckson	Independent Director	3.8yrs	US$99.20k	0% $ 0
Dawn Svoronos	Independent Director	3.9yrs	US$106.70k	0.024% $ 37.8k
Mark Lupher	Independent Director	5.5yrs	US$99.20k	0.062% $ 98.3k
Charles Wykoff	Scientific Advisory Board Member	no data	no data	no data
Arshad Khanani	Scientific Advisory Board Member	no data	no data	no data
Szilard Kiss	Director	less than a year	no data	no data

4.5yrs

Average Tenure

63yo

Average Age

Experienced Board: 0HA3's board of directors are considered experienced (4.5 years average tenure).

Adverum Biotechnologies Management

Management criteria checks 3/4

Key information

Recent management updates

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Recent updates

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

Adverum Biotechnologies, Inc. Appoints Linda Rubinstein as Chief Financial Officer

Adverum Biotechnologies, Inc. Announces New Data from the OPTIC Study Treating Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After A Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Adverum Biotechnologies, Inc. Completes IND Amendment and Prepares to Initiate Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 2000 Dynamic Index

Adverum Biotechnologies, Inc. Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After A Single IVT Injection of ADVM-022 in the Optic Study in Wet AMD

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies Announces New Data At the Macula Society's 2022 Annual Meeting

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of Its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

Adverum Biotechnologies, Inc. Presents Data At American Society of Gene and Cell Therapy Further Supporting Phase 2 Development Plans for ADVM-022

Adverum Biotechnologies, Inc. Presents Additional Efficacy and Safety Data from the Optic Trial of ADVM-022 in Wet AMD At the ARVO 2022 Annual Meeting

High number of new directors

Adverum Biotechnologies, Inc. Appoints Richard Beckman M.D. as Chief Medical Officer

Adverum Biotechnologies, Inc. Grants Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Independent Director recently sold US$109k worth of stock

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Adverum Biotechnologies, Inc. Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 3000E Growth Index

Independent Chairman recently bought US$99k worth of stock

Lexeo Therapeutics, LLC Announces License Agreement with Adverum Biotechnologies, Inc

Adverum Biotechnologies, Inc. Appoints Reed V. Tuckson as an Independent Member to Board of Directors

Adverum Biotechnologies, Inc. Appoints Christopher J. Derespino as Chief Business Officer

Adverum Biotechnologies, Inc. Appoints Leone Patterson as Principal Financial Officer and Principal Accounting Officer

Independent Chairman recently bought US$115k worth of stock

Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME

Adverum Biotechnologies, Inc Appoints Dawn Svoronos as Independent Member of Board of Directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age